Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Health Stock Jumps 6.6 Percent on Positive Study in Postmenopausal Women

NEW YORK (GenomeWeb News) — Shares in Genomic Health were up 6.56 percent, or $1.26, at $20.47 in mid-afternoon trading after the company this morning said its Oncotype DX showed positive results in predicting the likelihood of recurrent breast cancer in postmenopausal women.
 
The test is currently used to predict recurrence and the likelihood of benefit from chemotherapy in women with estrogen-receptor positive, node-negative breast cancer.
 
The study in postmenopausal women, conducted by the Southwest Oncology Group, a National Cancer Institute clinical trials cooperative group, will be submitted for presentation at the 30th Annual San Antonio Breast Cancer Symposium in December.
 
According to a report in the Associated Press, Cantor Fitzgerald analyst George Zavoico said the new indication, if approved, would increase the number of patients eligible for the test annually by as much as 20 percent, or between 125,000 and 145,000 from between 100,000 and 120,000.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.